Charles A. Henriques NeurogesX Inc.15% owner. QUTENZA developer - Non-Opioid Pain Therapies For Unmet Needs In Neuropathic Pain San Francisco Bay AreaPharmaceuticals Current Charles A. Henriques at Neuropathic Pain Investor Past Global Marketing Director at Self-employed Education Sacred Heart University Fairfield CT BS/BA Business Administration Summary Charles A. Henriques increased stake in NeurogesX, Inc. Filed SC 13G/A form with U.S. Securities and Exchange Commission on February 13,... Less Top 10 A A A profiles | LinkedIn View the profiles of professionals named A A A on LinkedIn. There are 21,706 professionals named A A A, who use LinkedIn to exchange information, ideas, and opportunities.
SNOA (MC $23 M) (Cash $13 M) Shares Out: 4.3 M / 17 FDA approved products some of them are in early launch phase plus additional Product launches expected within 6 months / Profitable in 2018 = 1000%+ UPSIDE POTENTIAL..GLTA
Sonoma Pharma (Nasdaq: SNOA)
Market Cap: 22.1 Million Cash: $12.6 Million Price: $5.15
Driving to commercial EBITDAS breakeven, without dilution
Grow current product portfolio with all sales people
•Alevicyn HydroGel, Dermal Spray & Spray Gel for atopic dermatitis & dermal procedures •Celacyn for scar treatment •Mondoxyne for severe acne –launched late 2015 •Ceramax for skin repair in atopic dermatitis–launched in April 2016 •SebuDerm for seborrhea dermatitis –launched in November 2016
Launch 3 New Products –our product pipeline –one every other quarter
•Launching Loyon–Fall 2017 •Ceramax in foam and gel forms –Q4 2017 & Q1 2018
Launch and Grow New and Current Products: During fiscal year 2017, we launched four new dermatology products, including SebuDerm™, Ceramax™, Lasercyn™ Gel and Lasercyn™ Dermal Spray, bringing us to a total of eight dermatology products for the treatment of atopic and seborrheic dermatitis, scar management, surgical procedures, severe acne and “state of the art” skin repair technology. We also obtained three new FDA clearances, now totaling 16 overall. Our strong intellectual property portfolio consists of 63 issued patents and 33 patent applications pending.
We plan to launch our new FDA approved product Loyon® (a skin descaler currently marketed in Europe) in the upcoming months and have a strong product pipeline of several product line improvements, including a line extension of Ceramax™. All in all, we believe this could possibly be our best product line of new FDA approved dermatology and skincare products yet, and we believe our innovation plan will help lead us to profitability.
NeurogesX Inc.15% owner. QUTENZA developer - Non-Opioid Pain Therapies For Unmet Needs In Neuropathic Pain San Francisco Bay AreaPharmaceuticals Current Charles A. Henriques at Neuropathic Pain Investor Past Global Marketing Director at Self-employed Education Sacred Heart University Fairfield CT BS/BA Business Administration Summary Charles A. Henriques increased stake in NeurogesX, Inc. Filed SC 13G/A form with U.S. Securities and Exchange Commission on February 13,...
Is BIIB undervalued? This sort of setup suggests potential upside... check out awe.some*sto-cks, its a pretty reliable service. of course you have to do your own due diligence, but they generally point you in the right direction.
if you bought the upgrade a day or two ago, you got snookered."'.Reuters reports that Democrats on the House Committee on Oversight and Government Reform have launched an investigation into price increases for multiple sclerosis (MS) drugs. Seven firms have received letters requesting information'....'".Of the seven firms contacted, Biogen has the largest exposure to the MS arena, accounting for more than 88% of its Q2 product sales"
“The system is broken.”
Drug Puts A $750,000 ‘Price Tag On Life’
The high cost of Spinraza, a new and promising treatment for spinal muscular atrophy, highlights how the cost-benefit analysis insurers use to make drug coverage decisions plays out in human terms.
whooz yor daddy
This was on Fidelity: ...11:38 ET - Biogen (BIIB) down 1%, as the stock reverses from pre-market gain of 2.9%. Shares jumped before the open based on big sales beat for Spinraza, company's new rare disease drug whose 2Q sales were nearly three times greater than analysts forecast. Jefferies says the decline during regular session driven by a mix of profit taking, lack of long term guidance from management, and other factors. Also hurting the stock is that company didn't announce any new share repurchases, and signaled there may not be any coming in near-term. BIIB will shift capital allocation away "from emphasizing share repurchases to prioritizing business development and investing for growth," CEO Michel Vounatsos says on conference call.
whooz yor daddy - Are you going to stop whining now???
Looks like Chevy was right, this stock is garbage. IBB and FBIOX are both near 52 week highs and that is WITHOUT AMGN, BIIB and other top holdings. All the recent bio sector gains are from the new kids. Between AMGNs earnings and the useless Italy news, what's this junk going to be at tomorrow like -70?
explain to me how the stock is down after that earnings report? I just don't get it.
AMAZING... Got a GS upgrade to $338 and we're already starting to sell off pre-market.
Cheers to all longs!!
biib >> LNTH
guys help i bought in premarket and im new with this...what should i do
This stock refuses to go higher even after good quarter and upgrades. It is DEAD money to me now!!! so frustrating
Headed to 240 just like the last earnings cycle
whooz yor daddy
Last ER Clancy sold a bunch of shares as he was exiting (4/25) stock sold off from its 291 high with vengeance. I am hopeful we won't have to worry about this scenario this time around Sure would like to see this north of $300 again. Long time since we've seen this.
What happened to all the acquisitions BIIB promised? All it did was buy one little drug. Same with GILD. They promised acquisitions too.
How is this Down ? Great report and raised guidance. PE is 16.5 with forward PE of 14. I have held since the 120's and will continue to hold. Regret not selling some in the 400's though